Report cover image

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 70 Pages
SKU # DEL18680180

Description

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2024



DelveInsight’s, ''Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Uterine leiomyomata (Uterine Fibroids) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Uterine leiomyomata (Uterine Fibroids) Understanding

Uterine leiomyomata or fibroids are an extremely common benign neoplasm in women of reproductive age. Although they are benign, they can have a significant impact on the everyday physical and mental well-being of women with this condition. Fibroids originate from uterine smooth muscle cells (myometrium) whose growth is primarily dependent on the levels of circulating estrogen. Further information regarding the pathogenesis of fibroids is poorly understood. Fibroids can either present as an asymptomatic incidental finding on imaging, or symptomatically. Common symptoms include abnormal uterine bleeding, pelvic pain, disruption of surrounding pelvic structures (bowel and bladder), and back pain. Uterine fibroids typically are seen in three significant locations: subserosal (outside the uterus), intramural (inside the myometrium), and submucosal (Inside the uterine cavity). They can further be broken down to pedunculated or not..

""Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uterine leiomyomata (Uterine Fibroids) pipeline landscape is provided which includes the disease overview and Uterine leiomyomata (Uterine Fibroids) treatment guidelines. The assessment part of the report embraces, in depth Uterine leiomyomata (Uterine Fibroids) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uterine leiomyomata (Uterine Fibroids) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Uterine leiomyomata (Uterine Fibroids). The therapies under development are focused on novel approaches to treat/improve Uterine leiomyomata (Uterine Fibroids).
Uterine leiomyomata (Uterine Fibroids) Emerging Drugs

Fezolinetant: Ogeda

Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women's health disorders. Fezolinetant's mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women.

Further product details are provided in the report……..

Uterine leiomyomata (Uterine Fibroids) : Therapeutic Assessment

This segment of the report provides insights about the Uterine leiomyomata (Uterine Fibroids) drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Uterine leiomyomata (Uterine Fibroids)
There are approx. 10+ key companies which are developing the therapies Uterine leiomyomata (Uterine Fibroids). The companies which have their Uterine leiomyomata (Uterine Fibroids) drug candidates in the most advanced stage, i.e phase II include Ogeda
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Uterine leiomyomata (Uterine Fibroids) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intravenous
  • Subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uterine leiomyomata (Uterine Fibroids) : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uterine leiomyomata (Uterine Fibroids) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uterine leiomyomata (Uterine Fibroids) drugs.

Uterine leiomyomata (Uterine Fibroids) Report Insights
  • Uterine leiomyomata (Uterine Fibroids) Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Uterine leiomyomata (Uterine Fibroids) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Uterine leiomyomata (Uterine Fibroids) drugs?
  • How many Uterine leiomyomata (Uterine Fibroids) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uterine leiomyomata (Uterine Fibroids)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uterine leiomyomata (Uterine Fibroids) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Uterine leiomyomata (Uterine Fibroids) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Bayer HealthCare Pharmaceuticals
  • Ogeda
  • Treadwell Therapeutics
  • Contex Therapeutics
  • Repros Therapeutics
  • Neurocrine Biosciences
Key Products
  • Vilaprisan
  • Fezolinetant
  • CFI 400945
  • CTX 030916
  • Telapristone
  • Elagolix

Table of Contents

70 Pages
Introduction
Executive Summary
Uterine leiomyomata (Uterine Fibroids) : Overview
What is Uterine leiomyomata (Uterine Fibroids)?
Types of Uterine leiomyomata (Uterine Fibroids)
Causes
Epidemiology and Risk Factors
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Uterine leiomyomata (Uterine Fibroids) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Vilaprisan: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Fezolinetant: Ogeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
CFI 400945: Contex Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Uterine leiomyomata (Uterine Fibroids) Key Companies
Uterine leiomyomata (Uterine Fibroids) Key Products
Uterine leiomyomata (Uterine Fibroids) - Unmet Needs
Uterine leiomyomata (Uterine Fibroids) - Market Drivers and Barriers
Uterine leiomyomata (Uterine Fibroids) - Future Perspectives and Conclusion
Uterine leiomyomata (Uterine Fibroids) Analyst Views
Uterine leiomyomata (Uterine Fibroids) Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us